Neurogene (NGNE) Total Liabilities (2013 - 2026)
Neurogene's (NGNE) quarterly Total Liabilities came in at $25.4 million in Q1 2026, up 7.88% YoY from $23.5 million in Q1 2025, and up 6.92% on a QoQ basis from $23.7 million in Q4 2025.
Neurogene (NGNE) Total Liabilities (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Total Liabilities data on file, last reported at $25.4 million in Q1 2026.
- Quarterly Total Liabilities rose 7.88% year-over-year to $25.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (up 7.88% YoY) and the FY2025 annual result came in at $23.7 million, down 6.46% from the prior year.
- Total Liabilities rose to $25.4 million in Q1 2026, from $23.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $36.5 million in Q4 2023 to a low of $10.6 million in Q4 2022.
- A 5-year average of $22.0 million and a median of $23.5 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities sank 47.85% — and 2023, when it surged 243.57%.
- Tracing NGNE's Total Liabilities over 5 years: stood at $10.6 million in 2022, then surged by 243.57% to $36.5 million in 2023, then tumbled by 30.63% to $25.4 million in 2024, then retreated by 6.46% to $23.7 million in 2025, then rose by 6.92% to $25.4 million in 2026.
- The last three Total Liabilities figures came in at $25.4 million (Q1 2026), $23.7 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 27.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.23 Mn |
| Mar 31, 2026 | 25.36 Mn |
| Dec 31, 2025 | 23.72 Mn |
| Sep 30, 2025 | 22.29 Mn |
| Jun 30, 2025 | 24.06 Mn |
| Mar 31, 2025 | 23.51 Mn |
| Dec 31, 2024 | 25.36 Mn |
| Sep 30, 2024 | 26.71 Mn |
| Jun 30, 2024 | 24.81 Mn |
| Mar 31, 2024 | 24.57 Mn |
| Dec 31, 2023 | 36.55 Mn |
| Sep 30, 2023 | 14.35 Mn |
| Jun 30, 2023 | 14.43 Mn |
| Mar 31, 2023 | 17.10 Mn |
| Dec 31, 2022 | 10.64 Mn |
| Sep 30, 2022 | 20.93 Mn |
| Jun 30, 2022 | 20.31 Mn |
| Mar 31, 2022 | 19.03 Mn |
| Dec 31, 2021 | 20.40 Mn |
| Sep 30, 2021 | 21.07 Mn |